Exploring the NK cell platform for cancer immunotherapy

2020/09/15 by Jacob A. Myers, Jeffrey S. Miller · 9 citations
Immunology and Microbiology · Medicine · #CAR-T cell therapy research #Immune Cell Function and Interaction #T-cell and B-cell Immunology

paper · doi:10.1038/s41571-020-0426-7

crossref issued 2020/09/15 · crossref published 2020/09/15 · crossref published-online 2020/09/15 · openalex publication_date 2020/09/15 · crossref created 2020/09/15 · crossref published-print 2021/02/01 · crossref deposited 2023/05/23 · openalex created_date 2025/10/10 · crossref indexed 2026/07/30 · openalex updated_date 2026/07/31

Cited by

• NK cell-based cancer immunotherapy: from basic biology to clinical development
• CAR-NK cell therapy combined with checkpoint inhibition induces an NKT cell response in glioblastoma
• Empowering Natural Killer Cells to Combat Acute Myeloid Leukemia: Perspective on CAR-NK Cell Therapy
• Nanoparticle-mediated efficient up-regulation of GSDMD-N to induce pyroptosis and enhance NK cell-based cancer immunotherapy
• Clinical, immunologic, and genetic characteristics of 148 patients with natural killer cell deficiency
• NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer
• CD49a Targeting Enhances NK Cell Function and Antitumor Immunity
• Optimizing the procedure for manufacturing clinical-grade genetically manipulated natural killer cells for adoptive immunotherapy
• NK cells in renal cell carcinoma and its implications for CAR-NK therapy
• The role of tumor microenvironment and immune cell crosstalk in triple-negative breast cancer (TNBC): Emerging therapeutic opportunities